Cytosorbents Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
129
- Stock Symbol
-
CTSO
- Investments
-
1
- Share Price
-
$4.35
- (As of Friday Closing)
Cytosorbents General Information
Description
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Contact Information
Website
www.cytosorbents.comCorporate Office
- 305 College Road East
- Princeton, NJ 08540
- United States
Corporate Office
- 305 College Road East
- Princeton, NJ 08540
- United States
Cytosorbents Stock Performance
As of 20-Nov-2026, Cytosorbents’s stock price is $4.35. Its current market cap is $13.1M with 3.15M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.35 | $5.13 | $2.84 - $17.00 | $13.1M | 3.15M | 37.1K | -$5.62 |
Cytosorbents Financials Summary
As of 30-Sep-2026, Cytosorbents has a trailing 12-month revenue of $37.5M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 37,302 | 59,745 | 71,127 | 67,593 |
| Revenue | 37,458 | 37,063 | 35,595 | 31,085 |
| EBITDA | (12,631) | (4,356) | (19,267) | (27,879) |
| Net Income | (17,502) | (8,198) | (20,719) | (29,247) |
| Total Assets | 37,160 | 44,182 | 47,372 | 52,956 |
| Total Debt | 29,574 | 29,111 | 26,893 | 18,313 |
Cytosorbents Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cytosorbents Comparisons
Industry
Financing
Details
Cytosorbents Competitors (4)
One of Cytosorbents’s 4 competitors is ExThera Medical, a Venture Capital-Backed company based in Martinez, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ExThera Medical | Venture Capital-Backed | Martinez, CA | ||||
| TerumoBCT | Formerly PE-Backed | Lakewood, CO | ||||
| Kimal | Formerly Accelerator/Incubator backed | Worcester, United Kingdom | ||||
| PreAnalytiX | Corporate Backed or Acquired | Hombrechtikon, Switzerland |
Cytosorbents Patents
Cytosorbents Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3237831-A1 | Improved cancer immunotherapy treatments | Pending | 29-Nov-2021 | ||
| EP-4440657-A1 | Improved cancer immunotherapy treatments | Pending | 29-Nov-2021 | ||
| EP-4440657-A4 | Improved cancer immunotherapy treatments | Pending | 29-Nov-2021 | ||
| US-20250009951-A1 | Improved cancer immunotherapy treatments | Pending | 29-Nov-2021 | ||
| WO-2023097334-A1 | Improved cancer immunotherapy treatments | Inactive | 29-Nov-2021 | A61M1/36 |
Cytosorbents Signals
Cytosorbents Acquisitions (1)
Cytosorbents’s most recent deal was a Merger/Acquisition with Gilder Enterprises. The deal was made on 30-Jun-2006.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Gilder Enterprises | 30-Jun-2006 | Merger/Acquisition | Internet Service Providers |
Cytosorbents ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.11 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Cytosorbents FAQs
-
When was Cytosorbents founded?
Cytosorbents was founded in 1997.
-
Where is Cytosorbents headquartered?
Cytosorbents is headquartered in Princeton, NJ.
-
What is the size of Cytosorbents?
Cytosorbents has 129 total employees.
-
What industry is Cytosorbents in?
Cytosorbents’s primary industry is Surgical Devices.
-
Is Cytosorbents a private or public company?
Cytosorbents is a Public company.
-
What is Cytosorbents’s stock symbol?
The ticker symbol for Cytosorbents is CTSO.
-
What is the current stock price of Cytosorbents?
As of 20-Nov-2026 the stock price of Cytosorbents is $4.35.
-
What is the current market cap of Cytosorbents?
The current market capitalization of Cytosorbents is $13.1M.
-
What is Cytosorbents’s current revenue?
The trailing twelve month revenue for Cytosorbents is $37.5M.
-
Who are Cytosorbents’s competitors?
ExThera Medical, TerumoBCT, Kimal, and PreAnalytiX are competitors of Cytosorbents.
-
What is Cytosorbents’s annual earnings per share (EPS)?
Cytosorbents’s EPS for 12 months was -$5.62.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process